Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Sofinnova Venture Partners X and related entities now report owning less than 5% of Vera Therapeutics’ Class A common stock. They beneficially own 2,793,987 shares, representing 3.9% of the company, based on 71,355,667 shares outstanding as of February 23, 2026.
The group’s ownership fell below the 5% threshold as of September 30, 2025, primarily because Vera Therapeutics sold additional shares over time. Venture investor Sofinnova characterizes its position as held for investment purposes and may buy more, sell, or distribute shares depending on market conditions and company developments.
Vera Therapeutics is a late clinical-stage biotech focused on serious immunological kidney diseases, led by atacicept for IgA nephropathy (IgAN). In a pivotal Phase 3 trial, atacicept achieved a 46% reduction in proteinuria (UPCR) from baseline and a 42% reduction versus placebo at week 36 (p<0.0001), with a safety profile generally comparable to placebo and fewer serious adverse events.
The company has filed a Biologics License Application for atacicept in IgAN, which received FDA priority review with a PDUFA target action date of July 7, 2026. Vera is also advancing atacicept in other autoimmune kidney diseases through the ORIGIN EXTEND and PIONEER studies, MAU868 for BK virus in kidney transplant recipients, and VT-109, a next‑generation dual BAFF/APRIL inhibitor, all supported by a broad global IP and licensing strategy.
Vera Therapeutics reported a larger full-year 2025 net loss of $299.6 million, or $4.66 per share, compared with a $152.1 million loss a year earlier, as research and development and general and administrative expenses rose to a combined $315.5 million. Net cash used in operating activities was $241.1 million.
The company ended 2025 with $714.6 million in cash, cash equivalents, and marketable securities and completed equity and debt financings with combined potential gross proceeds of $800 million, which it believes can fund operations beyond potential approval and U.S. commercial launch of atacicept. Vera highlighted positive Phase 3 ORIGIN data for atacicept in IgA nephropathy and noted the FDA has granted priority review to its Biologics License Application, with a PDUFA action date of July 7, 2026 and a planned U.S. launch in mid-2026, if approved.
Vera Therapeutics, Inc. Chief Medical Officer Robert Brenner reported a mandated sale of 2,151 shares of Class A Common Stock on February 23, 2026, at a weighted-average price of $41.9839 per share. The sale was an open-market “sell-to-cover” transaction required to satisfy tax withholding obligations from the vesting of restricted stock units under the company’s equity incentive plans and is described as non-discretionary. The trading orders for these tax-related sales occurred over two business days, from February 23 to February 24, 2026. After this sale, Brenner held 50,947 shares of Vera Therapeutics common stock directly.
Vera Therapeutics SVP of Finance Joseph R. Young reported an open-market sale of 3,117 shares of Class A common stock on February 23, 2026, at a weighted-average price of $41.9839 per share. The shares were sold solely to cover tax withholding on vesting RSUs under a mandated sell-to-cover arrangement and were not a discretionary trade. After this transaction, Young directly held 64,722 shares.
Vera Therapeutics, Inc. chief financial officer Sean Grant reported an open‑market sale of 4,949 shares of Class A common stock at a weighted‑average price of $41.9839 per share. According to the disclosure, the transaction was a mandated sell‑to‑cover trade to satisfy tax withholding obligations from vesting restricted stock units rather than a discretionary sale.
After this transaction, Grant directly held 114,181 Vera Therapeutics shares and indirectly held 5,000 additional shares through a trust. The sale occurred as part of trading orders executed over two business days beginning on February 23, 2026 and ending on February 24, 2026.
Vera Therapeutics president and CEO Marshall Fordyce reported a mandated sale of 16,925 shares of Class A common stock. The shares were sold in open-market "sell-to-cover" transactions solely to satisfy tax withholding obligations tied to vesting restricted stock units.
The weighted-average sale price was $41.9839 per share, with individual trades executed between $41.005 and $42.84 over two business days beginning on February 23, 2026. After these sales, Fordyce directly holds 257,163 shares, with additional indirect holdings of 122,949 shares held by a GRAT and 99,081 shares held by a trust.
Vera Therapeutics Chief Operating Officer David Lee Johnson reported an open-market sale of 2,579 shares of Class A common stock at a weighted-average price of $41.9839 per share. After this transaction, he directly owned 45,727 shares.
According to the disclosure, the shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plans. The sale was mandated by the company’s sell-to-cover election and is described as not a discretionary trade by the executive.
Vera Therapeutics, Inc. Chief Regulatory Officer William D. Turner reported an open-market sale of 2,187 shares of Class A common stock at a weighted-average price of $41.9839 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations from vesting restricted stock units under the company’s equity incentive plans and did not represent a discretionary trade by Turner. The trades to satisfy withholding occurred over two business days, from February 23 to February 24, 2026. After these transactions, Turner beneficially owned 45,313 shares of Class A common stock.
Vera Therapeutics Chief Commercial Officer Laurence Matthew Skelton reported an open-market sale of 1,582 shares of Class A common stock. The shares were sold on February 23, 2026 at a weighted-average price of 41.9839 per share to satisfy tax withholding obligations from vesting restricted stock units.
The sale was executed under the company’s equity incentive plans as a mandated “sell-to-cover” transaction and was not a discretionary trade by Skelton. After this sale, he beneficially owned 64,218 shares of Vera Therapeutics Class A common stock.